论文部分内容阅读
重症联合免疫缺陷(scid)小鼠移植人的骨髓细胞后立即或在一个月后用人的肥大细胞生长因子,白细胞介素3与粒,巨噬细胞集落刺激因子的融合物或二者联合治疗,可重建小鼠骨髓,产生多种人的分化细胞。如细胞因子联合治疗方案中包含有红细胞生成素,则外周血中可出现人的红细胞。在生长因子治疗的小鼠骨髓中含多向性,髓系和红系定向祖细胞。而未用生长因子治疗的小鼠骨髓中几乎无人的细胞或仅存在粒,巨噬细胞祖细胞。因此该系统可用于测定人的不成熟细胞,研究调节这些细胞的生长因子,建立人类造血系统疾病的动物模型。
Severe combined immunodeficient (scid) mice are treated with human mast cell growth factor, interleukin-3, granulocyte-macrophage colony-stimulating factor fusion, or both immediately or after one month after transplantation of human bone marrow cells, Mouse bone marrow can be reconstructed to produce a variety of human differentiated cells. Such as cytokines combined treatment options include erythropoietin, the human peripheral blood red blood cells can occur. Bone marrow of mice treated with growth factor contains multidirectional, myeloid and erythroid committed progenitor cells. However, almost no human bone marrow or only granulocyte and macrophage progenitor cells were found in the bone marrow of mice that were not treated with growth factors. Therefore, the system can be used to measure human immature cells, to study the growth factors that regulate these cells, and to establish animal models of human hematopoietic disorders.